- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01303757
A Novel Diet-Phenotype Interaction Affecting Body Weight (FRESH Start)
February 8, 2016 updated by: David S. Ludwig, MD, PhD, Boston Children's Hospital
The primary aim of the study is to examine insulin secretion as an effect modifier of the efficacy of a low-fat vs. low-glycemic load diet for weight loss among overweight/obese young adults in an 18-month, prospectively stratified, multi-center randomized controlled trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In recent years, diets of widely varying composition have been used in the treatment of obesity.
While none of these diets has produced consistent, long-term weight loss, some individuals on virtually all types of diets do remarkably well.
One explanation for this variation among individuals is differences in motivation and behavior.
However, underlying biological differences may also play an important role.
Previous work has identified insulin secretion (as quantified by serum insulin concentration at 30 minutes following a standard 75-gram oral glucose load) as an important biological determinant.
This randomized-controlled, multi-center trial aims to test the hypothesis that insulin secretion will predict which type of diet will work best for each individual.
A total of 160 obese young adults (18 to 40 years) will be assigned to one of two diets: low-fat (60% carbohydrate, 20% fat, 20% protein) or low-glycemic load (45% carbohydrate, 35% fat, 20% protein).
Participants will be enrolled at two sites (Children's Hospital Boston or University of North Carolina-Chapel Hill) and assigned to diet groups according to baseline insulin secretion status.
The protocol will include an intensive 6-month intervention period and a 12-month follow-up period.
Registered dietitians will provide nutrition education and behavioral counseling during group workshops and scheduled telephone calls.
In an effort to avoid confounding, close attention will be paid to control for treatment intensity, physical activity prescriptions, and behavioral methods between groups.
The primary endpoint will be percent body fat by DXA scan.
Secondary endpoints will include cardiovascular and diabetes risk factors.
Repeated, 24-hour dietary and physical activity recall interviews will provide process data.
Metabolomic profiling and molecular analysis of identified metabolites will be conducted to characterize phenotype and explore potential physiological mechanisms.
A successful outcome of this work will inform the practice of "personalized" nutritional therapy, enhancing the ability to select the most efficacious weight loss diet for an individual based on underlying biological differences.
Study Type
Interventional
Enrollment (Actual)
155
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
- University of North Carolina, Chapel Hill
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria
- Aged 18 to 40 years.
- Body mass index (BMI) ≥ 27 kg/m2.
- Body weight ≤ 300 lb.
- Access to a working telephone.
- Clearance in writing from a primary care provider (i.e., physician or nurse practitioner) to rule out pre-existing medical conditions.
- Willing and able to attend group workshops (for dietary intervention) on specified evenings.
Exclusion Criteria
- Physician diagnosis of a major medical illness or eating disorder.
- Chronic use of any medication that may affect study outcomes (e.g., insulin-sensitizing agents).
- Current smoking (i.e., 1 cigarette in the past week).
- Physical, mental, or cognitive handicaps that prevent participation.
- Another member of the family (i.e., first degree relative) or household participating in the study.
- Planning to relocate from current area of residence during the proposed timeframe for study participation.
- If female, planning to become pregnant during the 18 months of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Low glycemic load diet
|
|
|
Active Comparator: Low fat diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent body fat by dual-energy x-ray absorptiometry (DXA)
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Triglyceride
Time Frame: 18 months
|
18 months
|
|
HDL cholesterol
Time Frame: 18 months
|
18 months
|
|
LDL cholesterol
Time Frame: 18 months
|
18 months
|
|
C-reactive protein
Time Frame: 18 months
|
18 months
|
|
Plasminogen Activator Inhibitor-1
Time Frame: 18 months
|
18 months
|
|
Fasting blood glucose
Time Frame: 18 months
|
18 months
|
|
Insulin resistance
Time Frame: 18 months
|
18 months
|
|
Blood pressure
Time Frame: 18 months
|
18 months
|
|
Trunk fat
Time Frame: 18 months
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum insulin concentration 30 minutes following a standard 75-gram oral glucose load
Time Frame: 18 months
|
Effect modification
|
18 months
|
|
Metabolomic profile
Time Frame: 18 months
|
Effect modification
|
18 months
|
|
Insulin sensitivity
Time Frame: 18 months
|
Effect modification
|
18 months
|
|
Abdominal-to-total fat ratio
Time Frame: 18 months
|
Effect modification
|
18 months
|
|
Waist-to-hip ratio
Time Frame: 18 months
|
Effect modification
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Cara B Ebbeling, PhD, Boston Children's Hospital
- Study Director: Leslie Fischer, PhD, UNC Chapel Hill
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
February 22, 2011
First Submitted That Met QC Criteria
February 23, 2011
First Posted (Estimate)
February 25, 2011
Study Record Updates
Last Update Posted (Estimate)
February 9, 2016
Last Update Submitted That Met QC Criteria
February 8, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-04-0156
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Dietary counselling
-
Andalusian Regional Ministry of HealthAndaluz Health ServiceUnknownTobacco Smoking | Hypercholesterolemia | High Blood Pressure
-
University of Western MacedoniaCompletedHealthy Pregnant WomenGreece
-
National University of SingaporeRecruitingAging | Age Problem | Age-related Cognitive Decline | Age-Related AtrophySingapore
-
Wageningen UniversityRijnstate Hospital; Gelderse Vallei HospitalCompletedHeart Diseases | Cardiovascular Diseases | Vascular DiseasesNetherlands
-
University of TurkuAcademy of FinlandUnknownObesity | Immunology | Allergic DiseaseFinland
-
University of Nigeria, Enugu CampusUniversity of Glasgow; University Of Nigeria Teaching HospitalUnknownEssential HypertensionNigeria
-
Jens Rikardt AndersenCompletedDelayed Gastric Emptying | Hematological Disease | Malignant DiseaseDenmark
-
Eivind MelandUniversity of AgderCompleted
-
University of HelsinkiFazer GroupCompleted
-
Jens Rikardt AndersenCompleted